Safety and tolerability of SARS‐Cov‐2 vaccination in patients with myasthenia gravis: A multicenter experience

BACKGROUND AND PURPOSE: During the COVID‐19 pandemic, myasthenia gravis (MG) patients have been identified as subjects at high risk of developing severe COVID‐19, and thus were offered vaccination with priority. The lack of direct data on the safety and tolerability of SARS‐CoV‐2 vaccines in MG have...

Descripción completa

Detalles Bibliográficos
Autores principales: Farina, Antonio, Falso, Silvia, Cornacchini, Sara, Spagni, Gregorio, Monte, Gabriele, Mariottini, Alice, Massacesi, Luca, Barilaro, Alessandro, Evoli, Amelia, Damato, Valentina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Muscle and NMJ disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9111609/
https://www.ncbi.nlm.nih.gov/pubmed/35390184
http://dx.doi.org/10.1111/ene.15348

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9111609/
https://www.ncbi.nlm.nih.gov/pubmed/35390184
http://dx.doi.org/10.1111/ene.15348

Ejemplares similares